Jump to content

Eli Lilly and Company

From Alfawiki
Eli Lilly and Company
Company typePublic
IndustryPharmaceuticals
Founded1 January 1876; 150 years ago (1876-01-01) in Indianapolis, Indiana, United States
FounderEli Lilly
Headquarters
Indianapolis
,
United States
Area served
Worldwide (offices in 18 countries; products distributed in ~125 countries)
ProductsProzac, Cymbalta, Zyprexa, Humalog, Trulicity, Humulin, Basaglar, exenatide, Mounjaro, Zepbound
Websitewww.lilly.com

Eli Lilly and Company, commonly referred to as Lilly, is a prominent American pharmaceutical multinational headquartered in Indianapolis, Indiana. The company maintains offices across 18 nations and distributes its products in approximately 125 countries worldwide. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Civil War veteran, the business has evolved into a leading force within the global pharmaceutical sector.

As of October 2024, Lilly holds the distinction of being the world's most valuable pharmaceutical firm, boasting a market capitalization of $842 billion—an unprecedented figure for the industry. It occupies the 127th position on the Fortune 500 list with revenues amounting to $34.12 billion and ranks 221st on the Forbes Global 2000 as well as 252nd on Forbes' "America's Best Employers."

Lilly’s commercial focus is centered on several key pharmaceutical products such as Prozac (fluoxetine) for clinical depression, Cymbalta (duloxetine), and the antipsychotic medication Zyprexa (olanzapine). Its major sources of income derive from diabetes therapies including Humalog (insulin lispro) and Trulicity (dulaglutide). The company was instrumental in pioneering mass production of the polio vaccine and was among the earliest producers of human insulin via recombinant DNA technology, releasing products like Humulin, Humalog, and Basaglar—the first biosimilar insulin approved in the U.S. Additionally, Lilly introduced exenatide, the inaugural GLP-1 receptor agonist, followed by highly successful drugs Mounjaro and Zepbound (tirzepatide).

By 1997, Lilly had become Indiana’s largest corporation and a significant philanthropic contributor. In 2009, it incurred a $1.415 billion fine for unlawful marketing practices related to Zyprexa, marking the largest criminal penalty in healthcare at that time.

The company operates through a corporate structure designed to support its international activities via subsidiaries and holds memberships in leading industry bodies such as the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations.

Founding

The firm was founded in 1876 by Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist who remained president until his death in 1898. After gaining experience working in Indiana drugstores, Lilly partnered with James W. Binford in 1869 but departed in 1873 to return to Indianapolis. In 1874, he co-established Johnston and Lilly, a drug manufacturing enterprise.

In 1876, Lilly ended this partnership and initiated Eli Lilly and Company in Indianapolis, marking the beginning of his pharmaceutical venture. The enterprise started with three employees, including his son Josiah K. Lilly Sr., concentrating on products such as quinine for malaria treatment. By year-end, sales had reached $4,470.

19th century

In 1878, Eli Lilly appointed his brother James as the company’s first dedicated salesman, which expanded its drug marketing nationwide. Sales grew to $48,000 by 1879. In 1881, the company moved its Indianapolis headquarters to larger premises on South Meridian Street and acquired additional facilities for research and manufacturing. That same year, it formally incorporated as Eli Lilly and Company, established a board of directors, and issued shares to family members and associates.

Early innovations included gelatin-coated tablets, fruit-flavored medicines, and sugar-coated pills designed for easier consumption. In 1882, Josiah K. Lilly Sr., Colonel Lilly’s son and a pharmaceutical chemist, joined as laboratory superintendent. The company's first significant commercial success came with Succus Alteran in 1883—a blood purifier marketed for treating syphilis, rheumatism, and skin conditions—generating revenue that supported further manufacturing and research expansion.

By the late 1880s, employment exceeded 100 workers with annual sales surpassing $200,000 (adjusted to 2015 dollars). In 1890, Colonel Lilly transferred daily management responsibilities to J.K., who led the company for 34 years through economic fluctuations while expanding operations. The firm acquired a capsule production facility in 1894 and implemented automation to boost productivity.

After Colonel Lilly’s passing in 1898, J.K. assumed presidency. At that time, product offerings numbered 2,005 items with yearly sales over $300,000 (2015 dollars). Colonel Lilly had been a pioneer advocating ethical pharmaceutical standards; J.K. continued championing federal regulation of medicines.

The Indianapolis site grew into a substantial industrial complex encompassing more than two dozen buildings across fifteen blocks plus additional plants along Kentucky Avenue. Family involvement remained integral: alongside Eli Lilly and J.K., cousin Evan Lilly managed bookkeeping duties; grandsons Eli Jr. and Josiah Jr. later served as presidents and board chairs.

Under J.K.’s guidance, scientific management principles were adopted; research departments were formalized; sales forces expanded; and international distribution commenced. By century’s end, Eli Lilly & Co. produced sugar-coated tablets, elixirs, and syrups utilizing locally sourced materials combined with manual processes—while cautiously embracing scientific research relative to industry peers at that time.

20th century

In 1905, under the leadership of J. K. Lilly, the company experienced significant growth, with annual revenues reaching $1 million (equivalent to over $25 million in 2015). Before and following World War I, expansion accelerated, including increased production capacity at the McCarty Street facility, the addition of a Science Building in 1911, and a capsule manufacturing plant in 1913. That same year marked the beginning of construction for Lilly Biological Laboratories, a combined research and production site located near Greenfield, Indiana.

Lilly was an early adopter of automation and among the pioneers to encapsulate medications in gelatin capsules, enhancing dosage precision. By 1917, Scientific American recognized Lilly as "the largest capsule factory worldwide," capable of producing up to 2.5 million capsules daily. Innovations such as fruit-flavored medicines and sugar-coated tablets improved consumer acceptance. In 1909, Eli Lilly, the founder’s grandson, introduced blueprinting for manufacturing tickets to minimize errors.

In 1919, Josiah Lilly recruited biochemist George Henry Alexander Clowes to lead biochemical research. The 1920s saw the implementation of straight-line production in Building 22 (1926), which optimized operational efficiency and lowered costs—considered among the most sophisticated systems in the American pharmaceutical sector at that time. This advancement supported a steady workforce producing affordable medications throughout the year.

Financial growth was driven by product innovation. In 1921, Clowes secured an agreement with University of Toronto scientists to mass-produce insulin, hastening its commercial availability. By 1923, Lilly introduced Iletin, the first commercially available insulin product in the U.S., establishing a near monopoly until competitors appeared in 1924. Insulin remains one of Lilly’s cornerstone products, cementing its international pharmaceutical reputation.

By its 50th anniversary in 1926, the company’s sales had grown to $9 million with a portfolio exceeding 2,800 products. Collaborative efforts resulted in treatments such as Liver Extract 343 for pernicious anemia (1928), developed alongside Harvard scientists Minot and Murphy; their research earned them the Nobel Prize in 1934.

The 1930s marked Lilly’s initial international expansion with its first overseas subsidiary established in London (1934) and a manufacturing facility opened in Basingstoke. Despite economic challenges during the Great Depression, sales increased to $13 million by 1932. That year, Eli Lilly assumed company presidency, emphasizing production efficiency, scientific management principles, cost reduction strategies, and strengthening research alliances.

In 1934, new facilities including Lilly Research Laboratories were inaugurated on McCarty Street. During World War II, production expanded to include antibiotics like penicillin and antiseptics such as merthiolate; Lilly also processed substantial quantities of blood plasma for U.S. military use, supplying roughly one-fifth of the national demand.

By 1943, international operations had grown with the establishment of Eli Lilly International Corp., employing personnel across 35 countries by 1948. Postwar growth involved acquiring the Curtiss-Wright propeller plant on Kentucky Avenue for antibiotic and capsule manufacturing; employee numbers approached 7,000 by this period.

In 1948, after boosting sales from $13 million (1932) to $117 million, Eli Lilly retired as president; his brother Josiah K. Lilly Jr. took over as president and later served as chairman until 1966.

Mid-century developments included launching Tippecanoe Laboratories (1950) to enhance antibiotic production—particularly erythromycin—and introducing antibiotics such as vancomycin and erythromycin during the 1950s. Facing competition from generics in later decades prompted diversification into agrochemicals and veterinary pharmaceuticals through Elanco (established in 1954), as well as ventures into cosmetics and medical devices.

The company went public on the New York Stock Exchange in 1952; Eugene N. Beesley became its first president from outside the founding family in 1953. That year also marked expanded global reach through Elanco’s formation focused on veterinary pharmaceuticals.

Lilly played a pivotal role in producing Salk’s polio vaccine during clinical trials beginning in 1954 and manufactured approximately 60% of the vaccine supply upon its public release in 1955—building upon prior university research collaborations.

By the 1960s, Lilly operated thirteen international subsidiaries; it acquired The Distillers Company (1962), opened a large manufacturing plant in Liverpool, England, established its first overseas research center (Lilly Research Centre) in Surrey (1968), and inaugurated a new facility in Clinton, Indiana (1969).

Throughout the 1970s and ’80s, new pharmaceuticals were launched including Keflex (1971), Dobutrex (1977), Ceclor (1979), Eldisine for leukemia treatment, Oraflex for arthritis relief, and Darvon for pain management. In 1971, Lilly was added to the S&P 500 Index.

Diversification efforts included acquiring cosmetics manufacturer Elizabeth Arden for $38 million (1971); although initially unprofitable, Arden became successful under new leadership before being sold for $657 million in 1987.

Expansion into medical devices involved acquiring IVAC Corporation (vital signs monitors) and Cardiac Pacemakers Inc. (both in 1977), followed by Physio-Control (defibrillators) in 1980; these acquisitions formed a Medical Devices and Diagnostics Division that contributed roughly one-fifth of revenues by the early 1990s.

A joint agrochemical partnership with Dow Chemical established DowElanco (1989); Lilly divested its stake for $1.2 billion in 1997.

Leadership transitions included Vaughn Bryson becoming CEO in 1991 during which time the company reported its first quarterly loss as a publicly traded firm. Randall L. Tobias succeeded him as chairman, president, and CEO in 1993—the first CEO hired externally—implementing cost reductions and strategic realignment through divestitures alongside increased investment in research and development.

In 1994, Lilly acquired PCS Systems for $4 billion to enter drug benefits management services.

Sidney Taurel assumed CEO duties in 1998; that year also featured a joint venture with Icos Corporation aimed at developing Cialis for erectile dysfunction. Taurel became chairman in January 1999; by 2000 net sales had reached $10.86 billion.

21st century

In September 2002, Eli Lilly collaborated with Amylin Pharmaceuticals to develop exenatide, an innovative diabetes medication inspired by the venom of the Gila monster. This drug, recognized as the first GLP-1 receptor agonist, received FDA approval in April 2005.

By October 2006, Lilly had announced its intention to acquire Icos for $2.1 billion. Although initially met with opposition from institutional investors and the proxy advisory firm ISS due to concerns over undervaluation, the deal was finalized in January 2007. Following the acquisition, Lilly shuttered Icos' manufacturing facilities and downsized the workforce from nearly 500 employees to 127. Later that year, in December 2007, the biologics plant was sold to CMC Biopharmaceuticals, based in Copenhagen.

In January 2009, Lilly was subjected to a record $1.415 billion criminal penalty related to unlawful marketing practices of its antipsychotic medication Zyprexa.

In January 2011, Lilly and Boehringer Ingelheim entered into a global partnership aimed at co-developing diabetes treatments, with projected combined revenues exceeding $1.8 billion. The collaboration focused on Boehringer’s Linagliptin and Lilly’s insulin analogs LY2605541 and LY2963016.

April 2014 marked Lilly’s $5.4 billion acquisition of Novartis AG’s animal health division to strengthen Elanco’s portfolio. To comply with antitrust requirements, the Sentinel heartworm product was divested to Virbac.

In March 2015, Lilly secured a $690 million agreement with Hanmi Pharmaceutical for joint development of a Bruton's tyrosine kinase inhibitor and separately partnered with Innovent Biologics of China on oncology therapies valued at up to $456 million; this partnership extended through 2022. Additionally, Lilly resumed a Phase III trial collaboration with Pfizer for Tanezumab, including a $200 million upfront payment.

April 2015 saw Lilly engage CBRE Group to market its Vacaville, California biomanufacturing campus, one of the largest facilities in the United States.

Elanco expanded its vaccine portfolio in January 2017 by acquiring Boehringer Ingelheim Vetmedica's U.S. feline, canine, and rabies vaccines. In March of the same year, Lilly purchased CoLucid Pharmaceuticals for $960 million, gaining late-stage migraine treatment lasmiditan. By August 2017, Lilly and Shionogi licensed varespladib to Ophirex for development as a snakebite antidote.

Lilly enhanced its oncology pipeline in May 2018 through acquisitions of Armo Biosciences for $1.6 billion and AurKa Pharma for up to $575 million.

In January 2019, Lilly completed the acquisition of Loxo Oncology for around $8 billion, significantly broadening its cancer drug portfolio with TRK inhibitors such as Vitrakvi (Larotrectinib), LOXO-292 (RET inhibitor), LOXO-305 (BTK inhibitor), and LOXO-195. Later that year in August, Elanco acquired Bayer’s animal health business for $7.6 billion.

Lilly expanded its dermatology offerings in January 2020 by acquiring Dermira for $1.1 billion, obtaining assets including lebrikizumab and glycopyrronium cloth used for hyperhidrosis treatment.

By June 2020, partnering with Vancouver-based AbCellera, Lilly initiated the world’s first clinical trial of a monoclonal antibody treatment (LY-CoV555) targeting COVID-19. To support pandemic-related research in long-term care settings across the U.S., Lilly deployed mobile clinical units. In September 2020, Amgen joined forces with Lilly to manufacture COVID-19 antibody therapies.

In October 2020, Lilly submitted an emergency use authorization (EUA) request to the FDA for its COVID-19 antibody cocktail alongside competitor Regeneron. That month also saw Lilly acquire Disarm Therapeutics for up to $1.36 billion to advance SARM1 inhibitors aimed at preventing axonal degeneration.

Although NIH trials indicated limited benefit of bamlanivimab monotherapy in hospitalized COVID-19 patients, evidence supported its outpatient use; consequently, the FDA granted EUA for bamlanivimab in November 2020. December brought Lilly’s acquisition of Prevail Therapeutics for $1 billion to strengthen its gene therapy portfolio targeting neurodegenerative diseases.

In April 2021, the FDA withdrew bamlanivimab’s EUA due to emerging viral variants but approved Lilly’s application for Tyvyt (sintilimab) combined with chemotherapy for non-small cell lung cancer in May. July featured the purchase of Protomer Technologies for more than $1 billion.

Distribution of Lilly’s COVID-19 antibody treatments was paused in January 2022 amid concerns over the omicron variant; however, bebtelovimab received EUA supported by a $720 million U.S. government procurement contract.

The FDA authorized tirzepatide (Mounjaro) for type 2 diabetes treatment in May 2022. Following Indiana’s near-total abortion ban enacted in August that year, Lilly voiced apprehensions about attracting talent and signaled intentions to expand employment opportunities outside the state.

October 2022 saw Lilly acquire gene therapy firm Akouos Inc. for a total of $610 million.

In early 2020, Lilly introduced the Insulin Value Program providing insulin at $35 per monthly prescription regardless of insurance status; this initiative was later extended nationwide under the Inflation Reduction Act of 2023.

January 2023 involved a collaboration agreement with TRexBio focused on immune-mediated disease therapies featuring an upfront payment of $55 million. Subsequent acquisitions included Emergence Therapeutics and Sigilon Therapeutics (valued at $300 million), targeting treatments for obesity, diabetes, Alzheimer’s disease, and autoimmune disorders.

In July 2023, Lilly announced plans to acquire obesity drug manufacturer Versanis for $1.93 billion; followed by October’s purchase of oncology-focused Point Biopharma for approximately $1.4 billion.

The FDA approved tirzepatide under the brand name Zepbound for obesity management in November 2023.

By March 2024, Lilly partnered with Amazon to offer home delivery services for select medications via LillyDirect.

As of October 2024, driven by tirzepatide's blockbuster performance, Eli Lilly achieved status as the world’s most valuable pharmaceutical company with a market capitalization of $842 billion—the highest ever recorded—ranking second only behind Novo Nordisk.

Acquisition history

  • Eli Lilly and Company (established 1876)
    • Eli Lilly and Company
      • Distillers Company (acquired 1962)
      • Elizabeth Arden, Inc. (acquired 1971, divested Fabergé in 1987)
      • IVAC Corporation (acquired 1977)
      • Cardiac Pacemakers Inc. (acquired 1977)
      • Physio-Control Inc (acquired 1980)
      • Advance Cardiovascular Systems Inc. (acquired 1984)
      • Hybritech (acquired 1986)
      • Devices for Vascular Intervention Inc. (acquired 1986)
      • Pacific Biotech (acquired 1990)
      • Origin Medsystems (acquired 1992)
      • Heart Rhythm Technologies, Inc. (acquired 1992)
      • PCS System (acquired 1994)
      • Icos Corporation (acquired 2007)
      • Hypnion, Inc
      • ImClone Systems
      • SGX Pharmaceuticals, Inc (acquired 2008)
      • Avid Radiopharmaceuticals (acquired 2010)
      • Alnara Pharmaceuticals(acquired 2010)
      • CoLucid Pharmaceuticals (acquired 2017)
      • Armo Biosciences (acquired 2018)
      • AurKa Pharma (acquired 2018)
      • Loxo Oncology (acquired 2019)
      • Disarm Therapeutics (acquired 2020)
      • Prevail Therapeutics Inc (acquired 2020)
    • Elanco Products Company (originated in 1954 as an Eli Lilly division)
    • Protomer Technologies (acquired 2021)
    • Akouos Inc (acquired 2022)
    • Dice Therapeutics[1] (acquired 2023)
    • Emergence Therapeutics (acquired 2023)
    • Sigilon Therapeutics (acquired 2023)
    • Versanis Bio (acquired 2023)[2]
    • Mablink Bioscience (acquired 2023)
    • Point Biopharma (acquired 2023)

Collaborative research

Eli Lilly and Company has demonstrated a long-standing dedication to collaborative scientific inquiry. The company’s first dedicated research scientist, Ernest G. Eberhardt, joined in 1886, accompanied by botanists Walter H. Evans and John S. Wright, both alumni of Purdue University.

Following World War I, the organization expanded its facilities and leadership, steering its focus toward scientific research and development. In 1919, Josiah Lilly appointed biochemist George Henry Alexander Clowes as director of biochemical research. Clowes’s expertise and extensive academic connections were instrumental in establishing pivotal partnerships, including work with University of Toronto scientists who pioneered insulin development. This achievement cemented Lilly’s role as a frontrunner in pharmaceutical research, attracting leading researchers and fostering university collaborations.

By 1934, the company inaugurated a new research laboratory in Indianapolis and initiated clinical trials at Indianapolis City Hospital—a practice that remains integral to its drug validation process before market introduction.

In 1949, a collaboration with the United States Army Reserve led to the creation of a Strategic Intelligence Research and Analysis (SIRA) Unit dedicated to scientific logistics and Eurasian studies.

Further commitment to clinical research was demonstrated in 1998 with the establishment of additional laboratory facilities at Indiana University Medical Center in Indianapolis.

Publicly funded research

Eli Lilly collaborates on research projects financed by public funds in partnership with both academic institutions and industry players. One prominent initiative is the InnoMed PredTox consortium, which includes Lilly S.A. based in Switzerland, alongside various pharmaceutical firms and research entities. This project, sponsored by the European Commission, aims to improve drug safety through enhanced preclinical evaluations. In 2008, the consortium received an €8 million grant to support a 40-month endeavor managed by the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing Europe's innovative pharmaceutical and biotechnology sectors.

Moreover, Lilly has participated in programs under the Innovative Medicines Initiative (IMI), a collaborative effort between EFPIA and the European Commission designed to expedite pharmaceutical innovation across Europe. These partnerships are integral to Lilly’s strategic approach to drug development, helping sustain its competitive position in global markets.

Academia

Conferences and summits

  • World Neuroscience Innovation Forum, stakeholder sponsor

Media

Medical societies

Non-governmental organizations

Political lobbying

Professional organizations

  • Member of AdvaMed
  • Sponsor of the Canadian Rheumatology Association
  • Sponsor of the Canadian Urological Association
  • Donor to the Mood Disorders Association of Ontario (MDAO)

Public health initiatives

Research and innovation

  • Sponsor of Arthritis Australia
  • Sponsor of BioFIT, which hosts events linking academic institutions, pharmaceutical companies, and investors in life sciences and biotech sectors
  • Partner organization with the Canadian Consortium on Neurodegeneration and Aging
  • Sponsor of Colorectal Cancer Canada
  • Collaborator with pharmaceutical firms on COVID-19 treatments through the COVID-19 Therapeutics Accelerator
  • Corporate partner of Diabetes Canada
  • Event sponsor for GIANT Health, focusing on digital advancements in pharmaceuticals
  • Corporate partner of the Juvenile Diabetes Research Foundation (JDRF)
  • Sponsor of New Brunswick Health Research Foundation (NBHRF)
  • Sponsor and contract research organization (CRO) through Pinnacle Research Group
  • Industry partner providing specialized products and services via Radcliffe Cardiology

Pharmaceutical product portfolio

Prior to World War II, the company’s primary offerings included insulin marketed as Iletin (Insulin, Lilly), Amytal, Merthiolate, ephedrine, and liver extracts. During World War II, production expanded to incorporate penicillin and various antibiotics, antimalarial drugs, blood plasma, vaccines targeting encephalitis, typhus, influenza, gas gangrene antitoxin, Merthiolate, and Iletin.

Significant pharmaceutical innovations encompass cephalosporin, erythromycin, and Prozac (fluoxetine), a selective serotonin reuptake inhibitor (SSRI) used for treating clinical depression. Ceclor, launched in the 1970s, was an oral cephalosporin antibiotic. Prozac became Lilly’s top-selling antidepressant in the 1980s but lost its U.S. patent exclusivity in 2001. The company continues to be the largest global producer of medications addressing psychiatric and mental health disorders such as clinical depression, generalized anxiety disorder, addiction, insomnia, bipolar disorder, and schizophrenia.

In March 2023, Eli Lilly announced a $35 monthly cap on insulin prices to comply with provisions under the Inflation Reduction Act, reflecting its strategic approach to managing pricing challenges.

Major revenue contributors include Trulicity, Mounjaro, Verzenio, Taltz, Jardiance, Humalog, Cyramza, Olumiant, Emgality, Tyvyt, Retevmo, Alimta, and Zepbound.

Cialis

Eli Lilly launched Cialis in 2003 as a competitor to Pfizer’s Viagra for erectile dysfunction treatment. Cialis provides an active duration of 36 hours and was developed through a collaboration with biotechnology company Icos Corporation. Lilly acquired Icos in December 2006 to gain full ownership of Cialis.

Cymbalta

Cymbalta (duloxetine), a serotonin and norepinephrine reuptake inhibitor created by Eli Lilly, stands as a prominent antidepressant for treating major depressive disorder and generalized anxiety disorder. It competes financially with drugs like Prozac, ranking among the most lucrative pharmaceuticals in the industry. Additionally, Cymbalta is prescribed for conditions such as fibromyalgia, neuropathic pain, chronic pain syndromes, and osteoarthritis, significantly bolstering Lilly’s revenue streams.

Kisunla

Kisunla (donanemab) is a monoclonal antibody that received FDA approval in 2024 for managing Alzheimer’s disease. This medication marks a strategic move by Lilly to broaden its portfolio into neurodegenerative disorders, addressing an expanding market despite concerns over pricing in certain regions including the United Kingdom.

Gemzar

Introduced by the FDA in 1996, Gemzar (gemcitabine) serves as a fundamental chemotherapy agent primarily used against pancreatic cancer and non-small cell lung cancer. Its application in combination with 5-FU chemotherapy and radiation therapy highlights its critical role within oncology, reinforcing Lilly’s strong foothold in cancer treatment solutions.

Methadone

Eli Lilly pioneered the distribution of methadone in the United States under the brand name "Dolophine" beginning in 1947. Widely utilized for opioid dependency treatment, methadone continues to be a cornerstone in addiction medicine. Lilly acquired commercial rights to methadone for only one dollar post-World War II due to confiscated German patents, exemplifying a strategic expansion of its analgesic product range.

Prozac

Prozac was among the earliest medications designed to treat clinical depression by inhibiting serotonin reuptake in the brain. Approved by the FDA in 1987, it became a flagship product for Lilly until generic alternatives entered the market after 2002.

Secobarbital

Lilly manufactured Secobarbital, a barbiturate with anesthetic, sedative, anticonvulsant, and hypnotic effects, marketed under the name Seconal. It was prescribed for epilepsy management, short-term insomnia relief, and as an anesthetic for minor surgical procedures. Production ceased in 1999 due to advancements in therapeutic alternatives. The drug gained notoriety during the 1970s for recreational misuse and was associated with several high-profile fatalities, which affected its commercial viability.

Thiomersal

Thiomersal, developed by Lilly and introduced in 1930 as merthiolate, is a mercury-containing antiseptic used as a vaccine preservative. Despite controversies linking it to neurological conditions, legislation enacted from 2002 onward provided legal protection to Lilly against related lawsuits. Its utilization has markedly decreased since the mid-2000s.

Zyprexa

Zyprexa (Olanzapine), indicated for schizophrenia and bipolar disorder—including off-label applications—was launched in 1996 and remained Lilly’s top-selling medication until patent expiration in 2010.

Leadership

After three generations of leadership within the Lilly family beginning with founder Colonel Eli Lilly and his heirs, a corporate restructuring in 1944 segmented the company into smaller divisions overseen by vice presidents. This reorganization paved the way for growth and separated ownership from operational management. In 1953, Eugene N. Beesley became the first president from outside the family, initiating a transition toward professional management while family members retained board chairmanship roles until 1969.

Richard Donald Wood assumed the roles of president and CEO in 1972, followed by Vaughn Bryson in 1991 during whose tenure the company experienced its first quarterly loss as a publicly traded entity. In 1993, Randall L. Tobias—previously an AT&T vice chairman and board member since 1986—was appointed chairman, president, and CEO, marking an external executive leading the firm.

Sidney Taurel advanced from COO to CEO in 1998 and chairman in 1999, providing strategic direction until retiring as CEO in 2008. John C. Lechleiter succeeded him as CEO and president in April 2008 after serving as president and COO since 2005.

In July 2016, David Ricks took over as CEO from Lechleiter, continuing to drive Lilly’s focus on innovation and growth through executive leadership continuity.

Community involvement

The Lilly family and Eli Lilly and Company have demonstrated a deep-rooted dedication to serving their communities. Around 1890, leadership of the company passed from Col. Lilly to his son Josiah, who guided the firm for many years while actively engaging in civic initiatives. Josiah supported various local groups such as the Commercial Club of Indianapolis (which later became the Indianapolis Chamber of Commerce) and the Charity Organization Society, an early form of what is now the Family Services Association of Central Indiana, supported by United Way. Philanthropic efforts were also carried forward by Josiah's sons, Eli and Joe, who contributed to cultural and educational projects.

Josiah Sr. initiated the company’s legacy of disaster assistance by sending medical supplies after the 1906 San Francisco earthquake and providing support following the 1936 Johnstown Flood. During World War I in 1917, Lilly Field Hospital 32 was dispatched abroad. In World War II, Eli Lilly produced more than 200 military-related items, including aviator survival kits and remedies for seasickness used during D-Day, as well as processing over two million pints of dried blood plasma by the war’s conclusion.

Lilly Endowment

The Lilly Endowment was created in 1937 by Josiah K. Lilly Sr. along with his sons Eli and Joe as a private charitable foundation funded with stock from Lilly. Today, this Endowment holds an 11.3% ownership stake in Eli Lilly and Company.

Eli Lilly and Company Foundation

Distinct from the Lilly Endowment, the Eli Lilly and Company Foundation was formed in 1968 as a tax-exempt corporate foundation financed through company earnings to support philanthropic activities.

BGH

In August 2008, Eli Lilly obtained rights from Monsanto to produce bovine growth hormone (BGH), a substance used to enhance milk yield in dairy cows. This acquisition broadened Eli Lilly’s animal health offerings. Nevertheless, BGH has been a subject of persistent debate due to concerns about animal welfare and potential effects on human health, which have influenced public perception of the company within this market sector.

340B

In 2021, Eli Lilly contested a Department of Health and Human Services advisory opinion that mandated drug manufacturers extend discounted pricing under the 340B Drug Pricing Program to contract pharmacies linked with hospitals, rather than limiting it solely to hospitals themselves. This legal challenge illustrates Eli Lilly’s calculated approach to managing pricing strategies and revenues within government healthcare frameworks, underscoring conflicts between regulatory adherence and financial objectives.

Prozac

In September 1989, Joseph T. Wesbecker killed eight individuals and wounded twelve before taking his own life. Family members and victims attributed his actions to Prozac, which he had begun using a month earlier. This tragedy led to lawsuits and widespread public concern, with attorneys citing Prozac as a factor in abnormal behavior patterns. Internally, Eli Lilly had been aware of adverse effects referred to as "activation syndrome" years prior but faced criticism for inadequate warnings. The connection between antidepressant use and suicide remains controversial.

In October 2004, the FDA mandated a boxed warning on all antidepressants concerning their use in children, extending this warning in 2006 to include adults aged 25 or younger. Further updates came in February 2018 when the FDA revised warnings after reviewing data from twenty-four clinical trials that indicated an increase in suicidal events risk from two percent to four percent compared with placebo.

Unlawful Promotion of Zyprexa

Eli Lilly encountered numerous legal challenges alleging that its antipsychotic medication olanzapine (Zyprexa) was linked to diabetes and other adverse health effects. Internal company documents revealed attempts to minimize awareness of risks such as considerable patient weight gain.

In 2006, the firm resolved about 8,000 lawsuits by paying $700 million, followed by an additional settlement in early 2007 involving roughly 18,000 claims for $500 million. These agreements brought the total Zyprexa-related settlements to $1.2 billion. Further settlements included a 2008 accord with Alaska and a $62 million payment distributed among 32 states and the District of Columbia addressing consumer protection issues. In 2009, four sales employees initiated qui tam lawsuits accusing Lilly of unlawful off-label marketing practices.

Lilly admitted guilt to a federal misdemeanor charge for promoting Zyprexa for unapproved indications, specifically targeting dementia treatment in elderly patients. The company consented to a $1.415 billion penalty package—comprising an $800 million civil settlement, a $515 million criminal fine (the largest ever imposed in a healthcare matter), and forfeiture of $100 million in assets. CEO John C. Lechleiter recognized the event as a significant setback and highlighted the implementation of enhanced compliance protocols.

Internal correspondence revealed persistent efforts to broaden off-label promotion despite known risks. This controversy severely affected Lilly’s public image and financial standing.

In 2020, attorney James Gottstein authored The Zyprexa Papers, chronicling the litigation and its impact on psychiatry and pharmaceutical industry accountability within the United States. The publication underscores how leaked internal documents unveiled Eli Lilly’s practices and influenced political discussions on drug marketing ethics.

Workplace Discrimination

In March 2021, Eli Lilly was sued by a former lobbyist alleging sex discrimination and describing a sexually hostile workplace environment. The dispute was resolved through a confidential settlement in June 2021.

Later that year, in September 2021, the company faced federal litigation accusing it of age discrimination by allegedly prioritizing millennial candidates in hiring quotas for sales roles.

Patent Litigation in Canada

Eli Lilly initiated a $500 million NAFTA claim against Canada in September 2013, arguing that the invalidation of patents for its medications Strattera and Zyprexa violated protections afforded to foreign investors. Canadian judicial rulings deemed Strattera’s clinical trials insufficiently comprehensive and concluded that Zyprexa’s patent did not fulfill promised utility requirements. Ultimately, Eli Lilly lost this case in 2017.

Unlawful Promotion of Evista

Evista is prescribed for preventing and treating osteoporosis among postmenopausal women.

In December 2005, Eli Lilly pleaded guilty and agreed to pay $36 million for illicitly marketing Evista. Sales personnel were instructed to promote the drug for unauthorized uses such as breast cancer prevention and cardiovascular disease treatment while sometimes withholding information regarding its unproven efficacy in reducing breast cancer risk.

Insulin Pricing Controversies

U.S. legislators questioned Eli Lilly alongside other insulin producers in January 2019 concerning steep increases in insulin costs, which nearly doubled from $2,900 to $5,700 annually for individuals with type 1 diabetes between 2012 and 2016.

In November 2022, a verified Twitter account impersonation falsely announced that Eli Lilly would provide free insulin, triggering a sharp decline in the company’s stock value. The firm subsequently issued clarifications to dispel the misinformation.

In 2023, Eli Lilly revealed plans to lower out-of-pocket expenses for insulin to $35 per month, reducing Humalog’s price from $275 to $66 monthly and offering insulin glargine at a discount of 78% compared to competitor Sanofi’s pricing. However, these price cuts do not extend to newer insulin products, which remain significantly costlier than prices from previous decades.

Bibliography

External links

  1. ↑ Lua error in Module:Citation/CS1/Configuration at line 2123: attempt to index field '?' (a nil value).
  2. ↑ Lua error in Module:Citation/CS1/Configuration at line 2123: attempt to index field '?' (a nil value).
Retrieved from "https://www.alfawiki.org/index.php?title=Eli_Lilly_and_Company&oldid=7965"